The Alzheimer’s disease drug development landscape
Abstract Background Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallma...
Guardado en:
Autores principales: | Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, Prisca S. Leferink, Sasja Heetveld, Jeffrey Cummings, Philip Scheltens, Everard G. B. Vijverberg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/75d2847abf9c4438ab9936c7a8f4ae9a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
por: Carely Hernandez, et al.
Publicado: (2022) -
Potential drug–drug interactions in Alzheimer patients with behavioral symptoms
por: Pasqualetti G, et al.
Publicado: (2015) -
Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
por: Rúben G. R. Pinheiro, et al.
Publicado: (2021) -
Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
por: Liang JH, et al.
Publicado: (2018) -
Alzheimer’s disease and language impairments: social intervention and medical treatment
por: Klimova B, et al.
Publicado: (2015)